Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Chimeric
Interleukin 6 (IL-6), cytokine
Protein
0.2 nM (reported value)
PBS with 1%BSA, 0.05% Tween 20, 5 mM MgCl2
25°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
[dGp][dGp][mCp][dAp][dGp][mGp][Bn-dUp][Bn-dUp][Pe-dUp][dGp][dGp][Nap-dUp][dAp][Bn-dUp][Bn-dUp][mAp][dAp][dCp][mAp][mCp][dGp][Bn-dUp][Bn-dUp][dAp][dAp][dGp][Bn-dUp][mCp][dGp][Bn-dUp][dGp][dGp] Refer to Figure in the publication and the visualization above for the sequence of the aptamer. Due to complex modifications to the sequence proposed by the publication authors, the structure of the aptamer cannot be estimated.
SL1025 (ID# 621)
66
6908.54 g/mole
227300 L/(mole·cm)
68.18%
4.40
30.39
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Gupta, Shashi, et al. "Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor." Journal of Biological Chemistry 289.12 (2014): 8706-8719.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.